• CHIR-99021 (CT99021): A Benchmark GSK-3 Inhibitor for Plurip

  2026-06-16

  CHIR-99021 (CT99021) is a highly selective small molecule inhibitor of glycogen synthase kinase-3 (GSK-3) used extensively in stem cell research. It enables precise modulation of Wnt/β-catenin signaling, supporting embryonic stem cell pluripotency and controlled differentiation. Its potency and specificity make it a standard for in vitro and in vivo pathway studies.

• Biotin Azide: Precision Labeling for Lipid Signaling and Can

  2026-06-15

  Explore how Biotin Azide, a high-purity biotinylation reagent, is revolutionizing bio-orthogonal chemical labeling for advanced studies in lipid metabolism and Wnt/β-catenin signaling—key pathways in cancer. This thought-leadership article bridges mechanistic insight with strategic protocol guidance, referencing recent discoveries in cholesterol-Fzd5 signaling and demonstrating how APExBIO's Biotin-azide empowers translational researchers from interactomics to clinical innovation.

• Annexin V, human recombinant: Precision Tools for Quantitati

  2026-06-15

  Explore how Annexin V, a leading phosphatidylserine binding protein, enables rigorous, quantitative apoptosis analysis. This article unpacks structural innovations and advanced workflows, offering unique insights for cell death research.

• Applied Workflows for Eicosapentaenoic Acid in Cardiovascula

  2026-06-14

  Eicosapentaenoic Acid (EPA) advances cardiovascular and immunometabolic research with its precise modulation of membrane dynamics and lipid profiles. This article delivers actionable workflows, troubleshooting strategies, and cross-domain insights, empowering researchers to extract maximal value from APExBIO’s high-purity EPA omega-3 fatty acid.

• Anlotinib Hydrochloride Suppresses Angiogenesis via Multi-TK

  2026-06-13

  This study demonstrates that anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, robustly inhibits angiogenesis by blocking VEGFR2, PDGFRβ, and FGFR1 signaling. These findings highlight its superior efficacy in restricting endothelial cell migration and capillary tube formation, framing anlotinib as a valuable tool for cancer research and anti-angiogenic assay development.

• Superoxide Dismutase Activity Assay Kit: Assay Precision, Me

  2026-06-12

  Explore the Superoxide Dismutase Activity Assay Kit for advanced SOD activity quantification. This article uniquely examines assay specificity, practical protocol optimization, and insights from recent literature to guide oxidative stress research.

• EZH2 Controls Mesenchymal Gene Repression in Breast Cancer C

  2026-06-12

  Gallardo et al. reveal that EZH2, the catalytic subunit of PRC2, directly represses mesenchymal genes to maintain the epithelial phenotype in breast carcinoma cells. This study establishes a conserved mechanism for PRC2-mediated regulation of epithelial-mesenchymal plasticity, with significant implications for cancer epigenetics research and therapeutic targeting.

• CHIR-99021 (CT99021): Optimizing Stem Cell Differentiation W

  2026-06-11

  CHIR-99021 (CT99021) enables precision control of Wnt/β-catenin and TGF-β/Nodal signaling, streamlining pluripotency and directed differentiation in advanced stem cell and organoid models. This article translates the latest organoid engineering breakthroughs into actionable protocols and troubleshooting strategies for maximizing reproducibility and lineage specificity.

• Masitinib (AB1010): Technical Guidance for KIT/PDGFR Researc

  2026-06-11

  Masitinib (AB1010) is a phenylaminothiazole-type tyrosine kinase inhibitor that facilitates selective inhibition of KIT, PDGFRα, and PDGFRβ in cancer, mastocytosis, and inflammatory disease research. It is best suited for DMSO-based workflows requiring targeted kinase inhibition and is not appropriate for applications necessitating broad-spectrum kinase inhibitors or aqueous/ethanol solubility.

• Foretinib (GSK1363089): Applied Workflows for Tumor Growth I

  2026-06-10

  Foretinib (GSK1363089) empowers researchers to dissect tumor growth, cell motility, and metastasis in robust in vitro and in vivo models. This guide translates mechanistic insights and reference-driven parameters into strategic workflows, with troubleshooting and protocol optimization for reproducible results.

• GW4064: Non-Steroidal FXR Agonist Workflows in Metabolic Res

  2026-06-10

  GW4064 stands out as a potent, selective non-steroidal FXR agonist for dissecting FXR/TLR4 and ferroptosis crosstalk in liver fibrosis and metabolic disease models. This guide details experimental workflows, troubleshooting, and recent innovations enabling rigorous use of GW4064 in advanced cellular and animal studies.

• Anlotinib Hydrochloride: Advanced Workflows for Angiogenesis

  2026-06-09

  Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, unlocks high-fidelity inhibition of angiogenesis for translational cancer research. This guide details experimental workflows, troubleshooting strategies, and applied insights, showing how to maximize robust, reproducible results with APExBIO’s benchmark compound.

• Toremifene (SKU A3884): Reliable SERM Solutions for Prostate

  2026-06-09

  This article delivers scenario-driven, evidence-based guidance for using Toremifene (SKU A3884) in hormone-responsive cancer research. Addressing real laboratory challenges, it demonstrates how APExBIO’s Toremifene delivers reproducibility, robust in vitro activity, and validated workflow compatibility for cell viability and signaling assays.

• CTCF's Role in Centromere Maintenance and Mitotic Fidelity

  2026-06-08

  The referenced study establishes that CTCF, a chromatin architectural protein, is essential for maintaining centromere integrity and ensuring proper chromosome alignment during mitosis. Using rapid, inducible CTCF degradation, the research reveals how its loss disrupts centromere mechanics, metaphase plate organization, and post-mitotic nuclear shape, providing new insight into the molecular safeguards of mitotic fidelity.

• Applied Strategies for U0126: Advanced MEK1/2 Inhibition Wor

  2026-06-08

  U0126 stands out as a robust, selective MEK1/2 inhibitor for dissecting MAPK/ERK signaling in cancer biology and autophagy research. This article delivers actionable workflows, troubleshooting tips, and cutting-edge insights from recent resistance studies, empowering researchers to optimize experimental outcomes.

7805 records 11/521 page Previous Next First page 上5页 1112131415 下5页 Last page